Logo
Global Digital Biomarkers Market 2020-2030

Global Digital Biomarkers Market 2020-2030

Bonafide Trust 26-08-2020 199 Pages Figures : 99 Tables : 91
Region : Global Category : Lifescience Medical Devices

Global digital biomarkers market will reach $22.54 billion by 2030, growing by 36.2% annually over 2020-2030 driven by rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare. Highlighted with 91 tables and 99 figures, this 199-page report “Global Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Region. Based on System Component, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Data Collection Tools • Digital Platforms • Mobile Apps • Desktop-based Software • Wearables • Biosensors Data Integration Systems Based on Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cardiovascular Diseases Neurodegenerative Disorders • Parkinson’s Disease • Multiple Sclerosis • Alzheimer’s Disease Sleep and Movement Diseases Psychiatric Disorders Chronic Pain Gastrointestinal Diseases Diabetes Respiratory Conditions Other Diseases Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Wellness • Disease Diagnosis • Personalised Medication • Drug Discovery and Development Based on Development Status, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Novel Digital Biomarkers • Original Digital Biomarkers • Approved Digital Biomarkers Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Biopharmaceutical Companies & Labs • Healthcare Providers • Insurance Payers Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, The Netherlands, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • RoW (Saudi Arabia, UAE, Israel) For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Actigraph LLC Akili Interactive Labs AliveCor Inc Altoida Inc Amgen Inc Bayer AG Biogen Inc Cambridge Cognition Plc Eli Lilly and Company Evidation Health, Inc. F. Hoffmann-La Roche Ltd Fitbit Inc GlaxoSmithKline Plc Happify Health Human API IXICO Plc Koninklijke Philips N.V. Medical Care Corporation Medopad Ltd Mindstrong Health Neurotrack Technology, Inc Novartis International AG Pfizer Inc. Quanterix Corporation Sanofi S.A. The Takeda Pharmaceuticals Company Limited Verily Life Sciences Winterlight Labs Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Read More

Card image cap

Interested in this report?
Get your FREE sample!

Requirement Gathering & Methodology
Data Collection Techniques
Our Research Team & Data Sourcing
Data Science & Analytical Tools
Data Visualization & Presentation Skills
Project/ Report Delivery & After Sales Services